Published in Innate Immun on August 26, 2009
Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol (2010) 4.07
Mammalian gut immunity. Biomed J (2014) 1.43
The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med (2010) 1.14
Epigenetic control of the host gene by commensal bacteria in large intestinal epithelial cells. J Biol Chem (2011) 1.06
Colonic mucosal DNA methylation, immune response, and microbiome patterns in Toll-like receptor 2-knockout mice. FASEB J (2011) 1.05
Innate immune signaling in defense against intestinal microbes. Immunol Rev (2012) 1.00
TLR-Dependent Human Mucosal Epithelial Cell Responses to Microbial Pathogens. Front Immunol (2014) 0.97
Colonic epithelial response to injury requires Myd88 signaling in myeloid cells. Mucosal Immunol (2012) 0.93
Epigenetic contribution to individual variation in response to lipopolysaccharide in bovine dermal fibroblasts. Vet Immunol Immunopathol (2013) 0.87
The effects of oral and enteric Campylobacter concisus strains on expression of TLR4, MD-2, TLR2, TLR5 and COX-2 in HT-29 cells. PLoS One (2013) 0.82
Age dependent changes in the LPS induced transcriptome of bovine dermal fibroblasts occurs without major changes in the methylome. BMC Genomics (2015) 0.81
Potential association between TLR4 and chitinase 3-like 1 (CHI3L1/YKL-40) signaling on colonic epithelial cells in inflammatory bowel disease and colitis-associated cancer. Curr Mol Med (2013) 0.81
Multiple roles of toll-like receptor 4 in colorectal cancer. Front Immunol (2014) 0.80
Human intestinal epithelial cells express interleukin-10 through Toll-like receptor 4-mediated epithelial-macrophage crosstalk. J Innate Immun (2014) 0.78
Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases. Front Immunol (2016) 0.77
Common NOD2/CARD15 and TLR4 Polymorphisms Are Associated with Crohn's Disease Phenotypes in Southeastern Brazilians. Dig Dis Sci (2016) 0.77
Exogenous MD-2 confers lipopolysaccharide responsiveness to human corneal epithelial cells with intracellular expression of TLR4 and CD14. Inflammation (2011) 0.76
Novel Immunomodulatory Flagellin-Like Protein FlaC in Campylobacter jejuni and Other Campylobacterales. mSphere (2015) 0.76
Novel biomarkers of fibrosis in Crohn's disease. World J Gastrointest Pathophysiol (2016) 0.76
Ingested soluble CD14 from milk is transferred intact into the blood of newborn rats. Pediatr Res (2013) 0.75
CpG-rich islands and the function of DNA methylation. Nature (1986) 24.90
Toll-like receptors in the induction of the innate immune response. Nature (2000) 12.23
Histone acetyltransferases. Annu Rev Biochem (2001) 10.00
Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev (2000) 9.36
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med (1999) 9.23
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009) 8.99
Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem (1999) 7.38
Innate immunity. N Engl J Med (2000) 7.03
Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol (1995) 6.99
Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol (2000) 6.68
Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol (2001) 6.62
HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol (1992) 6.50
Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun (2000) 5.65
Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol (2002) 5.41
Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 5.12
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67
Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest (2000) 4.60
A human colonic tumor cell line that maintains vectorial electrolyte transport. Am J Physiol (1984) 4.47
Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol (2000) 4.32
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Chemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235. Biochemistry (1967) 4.22
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem (1999) 3.53
Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology (2004) 3.11
Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem (2000) 3.06
Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology (2002) 2.80
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut (2006) 2.41
Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med (2003) 2.39
TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem (2002) 2.37
Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res (2002) 2.12
MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components. J Immunol (2001) 2.12
Modulation of barrier function during Fas-mediated apoptosis in human intestinal epithelial cells. Gastroenterology (2000) 2.07
A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res (2006) 2.02
Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem (2003) 1.78
Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res (2001) 1.78
Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol (2006) 1.69
Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis (2001) 1.56
TLR signaling at the intestinal epithelial interface. J Endotoxin Res (2003) 1.47
No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammation. Mol Med (2008) 1.46
Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. Gastroenterology (2001) 1.43
MD-2. Immunobiology (2006) 1.30
Innate mechanisms of epithelial host defense: spotlight on intestine. Am J Physiol (1999) 1.29
Epithelial cells and their neighbors. IV. Bacterial contributions to intestinal epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol (2005) 1.20
poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages. J Leukoc Biol (2008) 1.16
Lipid A-associated proteins provide an alternate "second signal" in the activation of recombinant interferon-gamma-primed, C3H/HeJ macrophages to a fully tumoricidal state. J Immunol (1987) 1.14
Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling. J Immunol (2004) 1.13
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol (2007) 1.10
Campylobacter jejuni induces secretion of proinflammatory chemokines from human intestinal epithelial cells. Infect Immun (2005) 1.07
Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv Exp Med Biol (2008) 1.07
Isolation of monomeric and dimeric secreted MD-2. Endotoxin.sCD14 and Toll-like receptor 4 ectodomain selectively react with the monomeric form of secreted MD-2. J Biol Chem (2008) 1.05
Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. Br J Cancer (2009) 1.05
Histone deacetylase complexes: functional entities or molecular reservoirs. FEBS Lett (2001) 1.02
Bacterial regulation of intestinal immune responses. Inflamm Bowel Dis (2000) 1.01
Inhibition of macrophage tumoricidal activity by glucocorticoids. J Immunol (1988) 1.00
Role of commensal bacteria in chronic experimental colitis: lessons from the HLA-B27 transgenic rat. Pathobiology (2003) 0.97
Identification of LPS-binding peptide fragment of MD-2, a toll-receptor accessory protein. Biochem Biophys Res Commun (2002) 0.96
Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling. Blood (2008) 0.94
MD-2 controls bacterial lipopolysaccharide hyporesponsiveness in human intestinal epithelial cells. Life Sci (2007) 0.88
Novel method for the purification and characterization of lipopolysaccharide from Escherichia coli D31m3. Prog Clin Biol Res (1995) 0.79
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
TLR signaling in the gut in health and disease. J Immunol (2005) 3.51
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol (2003) 2.96
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem (2002) 2.37
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35
Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat Genet (2003) 2.31
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16
TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology (2008) 2.06
Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol (2004) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93
Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology (2008) 1.89
Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75
Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
A family of ductile intermetallic compounds. Nat Mater (2003) 1.66
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol (2009) 1.66
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57
The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol (2007) 1.56
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet (2012) 1.52
Defects in mucosal immunity leading to Crohn's disease. Immunol Rev (2005) 1.48
TLR signaling at the intestinal epithelial interface. J Endotoxin Res (2003) 1.47
A decompositional approach to parameter estimation in pathway modeling: a case study of the Akt and MAPK pathways and their crosstalk. Bioinformatics (2006) 1.44
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.43
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease. Dig Dis Sci (2013) 1.40
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun (2008) 1.34
Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ Health Perspect (2013) 1.33
Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis (2007) 1.33
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology (2006) 1.20
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol (2010) 1.19
AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J Biol Chem (2009) 1.17
Stochastic roadmap simulation: an efficient representation and algorithm for analyzing molecular motion. J Comput Biol (2003) 1.15
IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One (2009) 1.15
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci (2009) 1.14
Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol (2009) 1.14
Mastoparan, a G protein agonist peptide, differentially modulates TLR4- and TLR2-mediated signaling in human endothelial cells and murine macrophages. J Immunol (2005) 1.14
Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res (2012) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep (2006) 1.12
Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet (2011) 1.10
TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10
A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis (2004) 1.07
The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.05
Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther (2010) 1.04
Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol (2003) 1.04
Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity. J Exp Med (2011) 1.02
Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2011) 1.02
Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol (2004) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2012) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2011) 1.01
Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol (2012) 1.00
Ulcerative colitis therapy: importance of delivery mechanisms. Rev Gastroenterol Disord (2005) 0.98
Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis (2006) 0.94
Cancer in inflammatory bowel disease: lessons from animal models. Curr Opin Gastroenterol (2012) 0.93
The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol (2010) 0.93
DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience. Cortex (2012) 0.92
Teaching NeuroImages: methotrexate leukoencephalopathy mimicking a transient ischemic attack. Neurology (2010) 0.90
Using robotics to fold proteins and dock ligands. Bioinformatics (2002) 0.89
Epigenetic stability, adaptability, and reversibility in human embryonic stem cells. Proc Natl Acad Sci U S A (2012) 0.89
Methane emissions from free-ranging cattle: comparison of tracer and integrated horizontal flux techniques. J Environ Qual (2008) 0.88
Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol (2007) 0.88
Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol (2004) 0.87
Aberrant expression of the polarity complex atypical PKC and non-muscle myosin IIA in active and inactive inflammatory bowel disease. Virchows Arch (2011) 0.87
How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis (2008) 0.86